206 related articles for article (PubMed ID: 32945648)
1. Synthetic Particles for Cancer Vaccines: Connecting the Inherent Supply Chain.
Xia Y; Song T; Hu Y; Ma G
Acc Chem Res; 2020 Oct; 53(10):2068-2080. PubMed ID: 32945648
[TBL] [Abstract][Full Text] [Related]
2. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
Aikins ME; Xu C; Moon JJ
Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
[TBL] [Abstract][Full Text] [Related]
3. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes.
Jeanbart L; Ballester M; de Titta A; Corthésy P; Romero P; Hubbell JA; Swartz MA
Cancer Immunol Res; 2014 May; 2(5):436-47. PubMed ID: 24795356
[TBL] [Abstract][Full Text] [Related]
4. Cascade Cytosol Delivery of Dual-Sensitive Micelle-Tailored Vaccine for Enhancing Cancer Immunotherapy.
Jiang D; Mu W; Pang X; Liu Y; Zhang N; Song Y; Garg S
ACS Appl Mater Interfaces; 2018 Nov; 10(44):37797-37811. PubMed ID: 30360105
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells.
Yoshikawa T; Okada N; Oda A; Matsuo K; Matsuo K; Kayamuro H; Ishii Y; Yoshinaga T; Akagi T; Akashi M; Nakagawa S
Vaccine; 2008 Mar; 26(10):1303-13. PubMed ID: 18255205
[TBL] [Abstract][Full Text] [Related]
6. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
[TBL] [Abstract][Full Text] [Related]
7. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
8. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response.
Yu X; Dai Y; Zhao Y; Qi S; Liu L; Lu L; Luo Q; Zhang Z
Nat Commun; 2020 Feb; 11(1):1110. PubMed ID: 32111828
[TBL] [Abstract][Full Text] [Related]
9. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
10. Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system.
Xu X; Hegazy WA; Guo L; Gao X; Courtney AN; Kurbanov S; Liu D; Tian G; Manuel ER; Diamond DJ; Hensel M; Metelitsa LS
Cancer Res; 2014 Nov; 74(21):6260-70. PubMed ID: 25213323
[TBL] [Abstract][Full Text] [Related]
11. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
12. Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens.
Pavlenko M; Leder C; Pisa P
Expert Rev Vaccines; 2005 Jun; 4(3):315-27. PubMed ID: 16026247
[TBL] [Abstract][Full Text] [Related]
13. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
[TBL] [Abstract][Full Text] [Related]
14. Extending antigen release from particulate vaccines results in enhanced antitumor immune response.
Kapadia CH; Tian S; Perry JL; Sailer D; Christopher Luft J; DeSimone JM
J Control Release; 2018 Jan; 269():393-404. PubMed ID: 29146244
[TBL] [Abstract][Full Text] [Related]
15. Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.
Chen PG; Hu HG; Sun ZY; Li QQ; Zhang BD; Wu JJ; Li WH; Zhao YF; Chen YX; Li YM
Mol Pharm; 2020 Feb; 17(2):417-425. PubMed ID: 31841011
[TBL] [Abstract][Full Text] [Related]
16. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
17. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
18. Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8⁺ T cells.
Muraoka D; Nishikawa H; Noguchi T; Wang L; Harada N; Sato E; Luescher I; Nakayama E; Kato T; Shiku H
Vaccine; 2013 Apr; 31(17):2110-8. PubMed ID: 23499606
[TBL] [Abstract][Full Text] [Related]
19. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
20. Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity.
Patel JM; Vartabedian VF; Kim MC; He S; Kang SM; Selvaraj P
Biotechnol Bioeng; 2015 Jun; 112(6):1102-10. PubMed ID: 25689082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
